Maureen Byrne, Tiffany Y Sia, Christopher Fong, Aliya Khurram, Michele Waters, Yelena M Kemel, Qin Zhou, Megha Ranganathan, Kara Long Roche, Dennis S Chi, Sally Saban, Michelle Wu, Nancy Varice, Jada G Hamilton, Jian Carrot-Zhang, Nadeem R Abu-Rustum, Alexia Iasonos, Lora H Ellenson, Diana Mandelker, Britta Weigelt, Carol L Brown, Carol Aghajanian, Zsofia Stadler, Ying L Liu
OBJECTIVES: Although genetic testing (GT) is universally recommended for patients with epithelial ovarian cancer (EOC), rates are low (34%). In 1/2019, we implemented mainstreaming-GT in parallel with tumor testing via MSK-IMPACT within oncology clinics. We sought to determine GT rates pre/post-mainstreaming and patient characteristics associated with GT. METHODS: Patients with newly diagnosed EOC seen at our institution from 7/1/2015-3/31/2022 were included. Clinical data were abstracted including social determinants of health (SDOH) variables, race/ethnicity, marital status, insurance, language, comorbidities, employment, and Yost index, a measure of socioeconomic status...
March 14, 2024: Gynecologic Oncology